SIGA Technologies Inc. - 2010 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: SIGA is a biodefense company focused on the research, development, and commercialization of antiviral products for serious infectious diseases and biological warfare agents. The company's lead product candidate is ST-246, an orally administered antiviral for smallpox. Revenue is derived almost exclusively from U.S. government grants and contracts (primarily NIH and DTRA).
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 | 2009 | 2008 |
|---|---|---|---|
| Revenues | $19.2 million | $13.8 million | $8.1 million |
| Net Loss | $(28.2) million | $(19.4) million | $(10.2) million |
| Loss Per Share (Basic/Diluted) | $(0.62) | $(0.52) | $(0.29) |
| Operating Expenses | $31.9 million | $25.7 million | $16.8 million |
| Cash & Short-Term Investments | $21.3 million | $19.5 million | $2.3 million |
| Long-Term Obligations (Warrants) | $10.5 million | $9.7 million | $4.5 million |
| Accumulated Deficit | $(122.5) million | $(94.3) million | $(72.2) million |
Note: The 2010 Net Loss includes a non-cash charge of approximately $16.0 million related to the increase in the fair value of common stock warrants classified as liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 39% to $19.2 million, driven by increased funding for broad-spectrum antiviral and arenavirus programs, as well as ST-246 development.
- Expense Increases: Research and Development (R&D) expenses rose 30% to $22.7 million due to expanded clinical testing, manufacturing of ST-246, and hiring of specialized personnel. Selling, General, and Administrative (SG&A) expenses increased 8% primarily due to higher legal fees related to ongoing litigation.
- Warrant Liability Impact: The net loss widened significantly due to a $16.0 million loss on the fair value adjustment of outstanding warrants, compared to $7.5 million in 2009.
- Liquidity: Cash and short-term investments increased to $21.3 million, bolstered by $13.2 million in proceeds from the exercise of options and warrants.
Outlook, Risks, and Contingencies
- BARDA Contract Status: In October 2010, HHS announced an intent to award SIGA a contract for 1.7 million courses of ST-246 for the Strategic National Stockpile. However, this was subject to a size protest. In February 2011, the 2009 Request for Proposal (RFP) was cancelled, and a new RFP was issued. SIGA has responded, but no award is guaranteed.
- Legal Proceedings: PharmAthene, Inc. is suing SIGA regarding ST-246 licensing obligations. PharmAthene seeks damages up to $1 billion. A trial concluded in early 2011, with a decision reserved. SIGA believes it has meritorious defenses but cannot estimate potential loss.
- Internal Controls: SIGA identified a material weakness in internal controls in 2009 regarding warrant accounting. Management states this weakness has been remediated as of December 31, 2010.
- Capital Needs: The company expects to continue incurring losses and will require additional financing to complete product development. Management believes current funds are sufficient for at least the next 12 months.
Key Facts for Investor Verification
- Revenue Concentration: Verify the sustainability of revenue streams, as 91% of 2010 revenue came from NIH contracts and grants.
- BARDA Procurement: Monitor the status of the new 2011 BARDA Smallpox RFP, as commercial success is heavily dependent on this government contract.
- PharmAthene Litigation: Track the outcome of the Delaware Court of Chancery trial, as damages claims could reach $1 billion.
- Warrant Liability: Assess the impact of outstanding warrants classified as liabilities, which fluctuate with stock price and significantly impact reported net loss.
- Development Timeline: Confirm progress on ST-246 clinical trials and the timeline for filing a New Drug Application (NDA), estimated at 30 months from the filing date.